Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
8.36
+0.18 (2.20%)
Apr 17, 2025, 4:00 PM EDT - Market closed

Maze Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Cash & Equivalents
196.8129.1699.92
Cash & Short-Term Investments
196.8129.1699.92
Cash Growth
574.99%-70.82%-
Prepaid Expenses
4.864.956.23
Total Current Assets
201.6734.11106.15
Property, Plant & Equipment
29.9234.9841.23
Long-Term Deferred Charges
4.6--
Other Long-Term Assets
4.352.412.58
Total Assets
240.5471.5149.96
Accounts Payable
1.942.021.59
Accrued Expenses
14.19.8114.87
Current Portion of Leases
4.634.494.32
Total Current Liabilities
20.6716.3220.78
Long-Term Debt
-20.08-
Long-Term Leases
2225.0527.73
Other Long-Term Liabilities
0.97--
Total Liabilities
43.6461.4548.51
Common Stock
000.02
Additional Paid-In Capital
47.2421.8412.79
Retained Earnings
-358.43-395.69-295.27
Total Common Equity
-311.18-373.85-282.46
Shareholders' Equity
196.910.05101.44
Total Liabilities & Equity
240.5471.5149.96
Total Debt
26.6349.6232.06
Net Cash (Debt)
170.18-20.4767.86
Net Cash Per Share
62.33-8.9433.76
Filing Date Shares Outstanding
43.82.322.01
Total Common Shares Outstanding
2.442.322.01
Working Capital
18117.7985.37
Book Value Per Share
-127.72-160.95-140.52
Tangible Book Value
-311.18-373.85-282.46
Tangible Book Value Per Share
-127.72-160.95-140.52
Machinery
17.3116.4716.08
Construction In Progress
0.030.06-
Leasehold Improvements
5.455.365.33
Updated Jan 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q